Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change $ Change
grade F $3.15 -5.97% -0.2
AEZS closed down 5.97 percent on Tuesday, February 21, 2017, on 76 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical AEZS trend table...

Date Alert Name Type % Chg
Feb 21 Fell Below 50 DMA Bearish 0.00%
Feb 21 Stochastic Sell Signal Bearish 0.00%
Feb 21 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Feb 16 NR7 Range Contraction -5.97%
Feb 15 Stochastic Reached Overbought Other -5.97%
Feb 13 Crossed Above 50 DMA Bullish -4.55%
Feb 9 Bullish Engulfing Bullish 6.78%
Feb 8 Calm After Storm Range Contraction 12.50%
Feb 7 NR7 Range Contraction 10.53%
Feb 7 Narrow Range Bar Range Contraction 10.53%

Older signals for AEZS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company’s product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company’s products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.59
52 Week Low 2.35
Average Volume 362,100
200-Day Moving Average 3.46
50-Day Moving Average 3.2
20-Day Moving Average 2.97
10-Day Moving Average 3.15
Average True Range 0.22
ADX 23.28
+DI 28.38
-DI: 20.79
Chandelier Exit (Long, 3 ATRs) 2.79
Chandelier Exit (Short, 3 ATRs) 3.01
Upper Bollinger Band 3.53
Lower Bollinger Band 2.41
Percent B (%b) 0.66
Bandwidth 0.377104